Psoriasis is an immune-mediated disease, with the interleukin (IL)-23/IL-17 axis currently
considered its main pathogenic pathway. Tyrosine kinase 2 (TYK2) is responsible for …

Purpose of the article Psoriasis is a chronic, immune-mediated, skin disease with a
significantly negative impact on patients' quality of life. Moderate-to-severe disease often …

Background Psoriasis, a chronic inflammatory disease dependent on the interleukin (IL)-
23/T helper cell 17 (Th17) pathway, is initiated through plasmacytoid dendritic cell activation …

Background Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, inhibits
cytokine signaling in psoriasis pathogenesis. Objective The objective of this study was to …

Background In the phase III POETYK PSO-1 and PSO-2 trials, deucravacitinib, an oral
selective allosteric tyrosine kinase 2 inhibitor, was well tolerated and efficacious over 1 year …

Objective The objective of this study was to review the safety and efficacy of deucravacitinib,
a tyrosine kinase 2 (TYK2) inhibitor for moderate to severe plaque psoriasis. Data Sources …

Background Effective, well-tolerated oral psoriasis treatments are needed. Objective To
compare the efficacy and safety of deucravacitinib, an oral, selective, allosteric tyrosine …

Introduction Deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that
demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe …

Psoriasis management may be challenging, particularly for moderate-to-severe forms of the
disease. Indeed, conventional systemic treatments are often avoided for contraindications or …

Background: Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates interleukin
(IL)-23, IL-12, and interferon (IFN) α/β signaling. Deucravacitinib is a novel, oral, selective …